NASDAQ:NK

NantKwest Competitors

$16.87
-1.82 (-9.74 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$16.53
Now: $16.87
$18.57
50-Day Range
$18.69
MA: $30.57
$42.25
52-Week Range
$2.52
Now: $16.87
$45.42
Volume2.28 million shs
Average Volume1.57 million shs
Market Capitalization$1.84 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.61

Competitors

NantKwest (NASDAQ:NK) Vs. FATE, TWST, DNLI, HALO, ADPT, and KOD

Should you be buying NK stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to NantKwest, including Fate Therapeutics (FATE), Twist Bioscience (TWST), Denali Therapeutics (DNLI), Halozyme Therapeutics (HALO), Adaptive Biotechnologies (ADPT), and Kodiak Sciences (KOD).

NantKwest (NASDAQ:NK) and Fate Therapeutics (NASDAQ:FATE) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

Institutional & Insider Ownership

9.4% of NantKwest shares are held by institutional investors. Comparatively, 99.7% of Fate Therapeutics shares are held by institutional investors. 71.7% of NantKwest shares are held by company insiders. Comparatively, 21.4% of Fate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares NantKwest and Fate Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NantKwest-76,658.58%-56.06%-46.93%
Fate Therapeutics-810.13%-35.51%-25.40%

Analyst Ratings

This is a summary of current recommendations and price targets for NantKwest and Fate Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NantKwest00103.00
Fate Therapeutics04902.69

NantKwest presently has a consensus target price of $18.00, suggesting a potential upside of 6.70%. Fate Therapeutics has a consensus target price of $108.3125, suggesting a potential upside of 38.88%. Given Fate Therapeutics' higher possible upside, analysts clearly believe Fate Therapeutics is more favorable than NantKwest.

Risk & Volatility

NantKwest has a beta of 2.61, indicating that its stock price is 161% more volatile than the S&P 500. Comparatively, Fate Therapeutics has a beta of 1.88, indicating that its stock price is 88% more volatile than the S&P 500.

Earnings and Valuation

This table compares NantKwest and Fate Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NantKwest$40,000.0046,116.25$-65,790,000.00($0.70)-24.10
Fate Therapeutics$10.68 million684.84$-98,150,000.00($1.44)-54.16

NantKwest has higher earnings, but lower revenue than Fate Therapeutics. Fate Therapeutics is trading at a lower price-to-earnings ratio than NantKwest, indicating that it is currently the more affordable of the two stocks.

NantKwest (NASDAQ:NK) and Twist Bioscience (NASDAQ:TWST) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

Institutional & Insider Ownership

9.4% of NantKwest shares are held by institutional investors. Comparatively, 87.9% of Twist Bioscience shares are held by institutional investors. 71.7% of NantKwest shares are held by company insiders. Comparatively, 7.0% of Twist Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares NantKwest and Twist Bioscience's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NantKwest-76,658.58%-56.06%-46.93%
Twist Bioscience-155.31%-44.62%-35.49%

Analyst Ratings

This is a summary of current recommendations and price targets for NantKwest and Twist Bioscience, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NantKwest00103.00
Twist Bioscience11202.25

NantKwest presently has a consensus target price of $18.00, suggesting a potential upside of 6.70%. Twist Bioscience has a consensus target price of $133.3333, suggesting a potential upside of 0.83%. Given NantKwest's stronger consensus rating and higher possible upside, equities research analysts clearly believe NantKwest is more favorable than Twist Bioscience.

Risk & Volatility

NantKwest has a beta of 2.61, indicating that its stock price is 161% more volatile than the S&P 500. Comparatively, Twist Bioscience has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500.

Earnings and Valuation

This table compares NantKwest and Twist Bioscience's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NantKwest$40,000.0046,116.25$-65,790,000.00($0.70)-24.10
Twist Bioscience$90.10 million71.39$-139,930,000.00($3.00)-44.08

NantKwest has higher earnings, but lower revenue than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than NantKwest, indicating that it is currently the more affordable of the two stocks.

Summary

NantKwest beats Twist Bioscience on 8 of the 14 factors compared between the two stocks.

NantKwest (NASDAQ:NK) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

Institutional & Insider Ownership

9.4% of NantKwest shares are held by institutional investors. Comparatively, 68.2% of Denali Therapeutics shares are held by institutional investors. 71.7% of NantKwest shares are held by company insiders. Comparatively, 19.3% of Denali Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares NantKwest and Denali Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NantKwest-76,658.58%-56.06%-46.93%
Denali Therapeutics-968.59%-39.19%-30.71%

Analyst Ratings

This is a summary of current recommendations and price targets for NantKwest and Denali Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NantKwest00103.00
Denali Therapeutics01702.88

NantKwest presently has a consensus target price of $18.00, suggesting a potential upside of 6.70%. Denali Therapeutics has a consensus target price of $75.8571, suggesting a potential upside of 45.15%. Given Denali Therapeutics' higher possible upside, analysts clearly believe Denali Therapeutics is more favorable than NantKwest.

Risk & Volatility

NantKwest has a beta of 2.61, indicating that its stock price is 161% more volatile than the S&P 500. Comparatively, Denali Therapeutics has a beta of 2, indicating that its stock price is 100% more volatile than the S&P 500.

Earnings and Valuation

This table compares NantKwest and Denali Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NantKwest$40,000.0046,116.25$-65,790,000.00($0.70)-24.10
Denali Therapeutics$26.68 million236.98$-197,610,000.00($2.07)-25.25

NantKwest has higher earnings, but lower revenue than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than NantKwest, indicating that it is currently the more affordable of the two stocks.

Summary

Denali Therapeutics beats NantKwest on 8 of the 14 factors compared between the two stocks.

NantKwest (NASDAQ:NK) and Halozyme Therapeutics (NASDAQ:HALO) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

Institutional & Insider Ownership

9.4% of NantKwest shares are held by institutional investors. Comparatively, 98.5% of Halozyme Therapeutics shares are held by institutional investors. 71.7% of NantKwest shares are held by company insiders. Comparatively, 2.6% of Halozyme Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares NantKwest and Halozyme Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NantKwest-76,658.58%-56.06%-46.93%
Halozyme Therapeutics10.78%24.29%4.08%

Analyst Ratings

This is a summary of current recommendations and price targets for NantKwest and Halozyme Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NantKwest00103.00
Halozyme Therapeutics01902.90

NantKwest presently has a consensus target price of $18.00, suggesting a potential upside of 6.70%. Halozyme Therapeutics has a consensus target price of $42.9167, suggesting a potential upside of 0.34%. Given NantKwest's stronger consensus rating and higher possible upside, equities research analysts clearly believe NantKwest is more favorable than Halozyme Therapeutics.

Risk & Volatility

NantKwest has a beta of 2.61, indicating that its stock price is 161% more volatile than the S&P 500. Comparatively, Halozyme Therapeutics has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500.

Earnings and Valuation

This table compares NantKwest and Halozyme Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NantKwest$40,000.0046,116.25$-65,790,000.00($0.70)-24.10
Halozyme Therapeutics$195.99 million31.27$-72,240,000.00($0.50)-85.54

NantKwest has higher earnings, but lower revenue than Halozyme Therapeutics. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than NantKwest, indicating that it is currently the more affordable of the two stocks.

Summary

Halozyme Therapeutics beats NantKwest on 8 of the 14 factors compared between the two stocks.

NantKwest (NASDAQ:NK) and Adaptive Biotechnologies (NASDAQ:ADPT) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

Institutional & Insider Ownership

9.4% of NantKwest shares are held by institutional investors. Comparatively, 80.8% of Adaptive Biotechnologies shares are held by institutional investors. 71.7% of NantKwest shares are held by company insiders. Comparatively, 22.2% of Adaptive Biotechnologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares NantKwest and Adaptive Biotechnologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NantKwest-76,658.58%-56.06%-46.93%
Adaptive Biotechnologies-132.32%-20.15%-13.09%

Analyst Ratings

This is a summary of current recommendations and price targets for NantKwest and Adaptive Biotechnologies, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NantKwest00103.00
Adaptive Biotechnologies02402.67

NantKwest presently has a consensus target price of $18.00, suggesting a potential upside of 6.70%. Adaptive Biotechnologies has a consensus target price of $61.40, suggesting a potential upside of 51.90%. Given Adaptive Biotechnologies' higher possible upside, analysts clearly believe Adaptive Biotechnologies is more favorable than NantKwest.

Risk & Volatility

NantKwest has a beta of 2.61, indicating that its stock price is 161% more volatile than the S&P 500. Comparatively, Adaptive Biotechnologies has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500.

Earnings and Valuation

This table compares NantKwest and Adaptive Biotechnologies' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NantKwest$40,000.0046,116.25$-65,790,000.00($0.70)-24.10
Adaptive Biotechnologies$85.07 million66.15$-68,610,000.00($1.01)-40.02

NantKwest has higher earnings, but lower revenue than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than NantKwest, indicating that it is currently the more affordable of the two stocks.

NantKwest (NASDAQ:NK) and Kodiak Sciences (NASDAQ:KOD) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

Institutional & Insider Ownership

9.4% of NantKwest shares are held by institutional investors. Comparatively, 82.3% of Kodiak Sciences shares are held by institutional investors. 71.7% of NantKwest shares are held by company insiders. Comparatively, 39.3% of Kodiak Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares NantKwest and Kodiak Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NantKwest-76,658.58%-56.06%-46.93%
Kodiak SciencesN/A-32.32%-23.86%

Analyst Ratings

This is a summary of current recommendations and price targets for NantKwest and Kodiak Sciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NantKwest00103.00
Kodiak Sciences17402.25

NantKwest presently has a consensus target price of $18.00, suggesting a potential upside of 6.70%. Kodiak Sciences has a consensus target price of $129.9091, suggesting a potential upside of 19.11%. Given Kodiak Sciences' higher possible upside, analysts clearly believe Kodiak Sciences is more favorable than NantKwest.

Risk & Volatility

NantKwest has a beta of 2.61, indicating that its stock price is 161% more volatile than the S&P 500. Comparatively, Kodiak Sciences has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500.

Earnings and Valuation

This table compares NantKwest and Kodiak Sciences' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NantKwest$40,000.0046,116.25$-65,790,000.00($0.70)-24.10
Kodiak SciencesN/AN/A$-47,370,000.00($1.25)-87.26

Kodiak Sciences has lower revenue, but higher earnings than NantKwest. Kodiak Sciences is trading at a lower price-to-earnings ratio than NantKwest, indicating that it is currently the more affordable of the two stocks.

Summary

Kodiak Sciences beats NantKwest on 7 of the 13 factors compared between the two stocks.


NantKwest Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Fate Therapeutics logo
FATE
Fate Therapeutics
1.8$77.99-1.3%$7.31 billion$10.68 million-42.39Analyst Revision
Twist Bioscience logo
TWST
Twist Bioscience
1.2$132.23-0.1%$6.43 billion$90.10 million-35.26Analyst Upgrade
Insider Selling
Denali Therapeutics logo
DNLI
Denali Therapeutics
1.5$52.26-1.4%$6.32 billion$26.68 million-23.65Insider Selling
News Coverage
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$42.77-1.3%$6.13 billion$195.99 million267.31
Adaptive Biotechnologies logo
ADPT
Adaptive Biotechnologies
1.6$40.42-4.0%$5.63 billion$85.07 million-42.55Insider Selling
News Coverage
Gap Down
Kodiak Sciences logo
KOD
Kodiak Sciences
1.5$109.07-1.1%$5.58 billionN/A-47.01
Vir Biotechnology logo
VIR
Vir Biotechnology
1.7$43.13-3.9%$5.52 billion$8.09 million-18.28Analyst Upgrade
Gap Down
China Biologic Products logo
CBPO
China Biologic Products
0.8$118.00-0.2%$4.64 billion$503.70 million32.96
Allogene Therapeutics logo
ALLO
Allogene Therapeutics
1.3$32.82-2.5%$4.62 billionN/A-15.41News Coverage
Gap Down
Iovance Biotherapeutics logo
IOVA
Iovance Biotherapeutics
1.7$30.19-3.7%$4.44 billionN/A-15.72Unusual Options Activity
News Coverage
Gap Down
Beam Therapeutics logo
BEAM
Beam Therapeutics
1.3$70.23-6.5%$4.39 billion$20,000.00-5.00News Coverage
Gap Down
SpringWorks Therapeutics logo
SWTX
SpringWorks Therapeutics
1.8$68.95-3.5%$3.38 billionN/A-39.63Gap Down
NanoString Technologies logo
NSTG
NanoString Technologies
1.3$70.33-0.1%$3.14 billion$125.57 million-41.13
Revolution Medicines logo
RVMD
Revolution Medicines
1.5$42.67-5.5%$3.13 billion$50.04 million0.00Insider Selling
Gap Down
Relay Therapeutics logo
RLAY
Relay Therapeutics
1.8$33.63-5.1%$3.04 billionN/A0.00Gap Down
Vericel logo
VCEL
Vericel
1.3$57.77-3.5%$2.66 billion$117.85 million-5,777,000.00News Coverage
Gap Down
Editas Medicine logo
EDIT
Editas Medicine
1.6$39.46-3.3%$2.66 billion$20.53 million-22.68
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.3$7.51-3.1%$2.11 billion$31.43 million-5.14News Coverage
Gap Down
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.6$23.88-1.0%$1.94 billionN/A-11.16
bluebird bio logo
BLUE
bluebird bio
1.8$28.16-2.5%$1.89 billion$44.67 million-2.56
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.5$10.21-1.9%$1.81 billion$48.83 million-13.43
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.02-2.1%$1.58 billion$102.43 million-18.37Analyst Upgrade
Gap Down
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$69.29-6.8%$1.54 billionN/A-46.82News Coverage
Gap Down
Immunovant logo
IMVT
Immunovant
1.8$15.68-1.4%$1.54 billionN/A-12.16Unusual Options Activity
AlloVir logo
ALVR
AlloVir
1.4$23.21-5.2%$1.51 billionN/A0.00Gap Down
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
1.2$33.44-4.6%$1.50 billionN/A0.00News Coverage
Gap Down
REGENXBIO logo
RGNX
REGENXBIO
1.6$35.17-0.0%$1.49 billion$35.23 million-14.18News Coverage
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.4$32.66-3.2%$1.41 billionN/A0.00Insider Selling
High Trading Volume
News Coverage
Gap Down
Replimune Group logo
REPL
Replimune Group
1.5$30.07-1.9%$1.40 billionN/A-16.99
Alector logo
ALEC
Alector
1.3$17.37-13.0%$1.38 billion$21.22 million-7.79Insider Selling
Gap Down
Ocugen logo
OCGN
Ocugen
1.1$6.96-0.7%$1.31 billionN/A-4.70Gap Up
Translate Bio logo
TBIO
Translate Bio
1.6$17.26-2.1%$1.30 billion$7.80 million-16.13
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.4$13.77-3.1%$1.15 billionN/A-2.98Gap Down
Forma Therapeutics logo
FMTX
Forma Therapeutics
1.8$27.90-0.9%$1.15 billion$100.56 million0.00
Mesoblast logo
MESO
Mesoblast
1.4$8.51-0.6%$1.10 billion$32.16 million-9.67Analyst Upgrade
News Coverage
Curis logo
CRIS
Curis
1.3$11.50-2.9%$1.05 billion$10 million-14.02Gap Down
Vaxcyte logo
PCVX
Vaxcyte
1.7$20.22-2.7%$1.04 billionN/A0.00
Scholar Rock logo
SRRK
Scholar Rock
1.5$29.94-6.2%$1.03 billion$20.49 million-12.42Gap Down
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$13.95-1.1%$1.02 billion$356.07 million6.84
Cortexyme logo
CRTX
Cortexyme
1.3$33.59-6.9%$992.65 millionN/A-14.00Gap Down
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$20.10-5.8%$922.43 million$42.74 million-223.33Gap Down
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$24.63-0.9%$890.08 millionN/A-4.07
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.7$9.08-6.9%$887.99 million$250,000.00-7.15News Coverage
Gap Down
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$18.83-0.7%$883.45 million$69.89 million-4.49
Passage Bio logo
PASG
Passage Bio
1.8$16.34-4.4%$879.60 millionN/A0.00News Coverage
Gap Down
Cellectis logo
CLLS
Cellectis
1.3$19.92-1.6%$852.18 million$22.99 million-10.60News Coverage
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.6$22.02-2.8%$839.78 millionN/A-9.10News Coverage
Gap Down
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$6.73-3.7%$832.47 million$2.51 million-4.08Gap Down
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$21.47-5.4%$818.93 millionN/A0.00Lockup Expiration
Gap Up
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$21.19-6.0%$800.16 millionN/A0.00Gap Up
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.